1. Home
  2. TACT vs XLO Comparison

TACT vs XLO Comparison

Compare TACT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

HOLD

Current Price

$4.13

Market Cap

41.6M

Sector

Technology

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.69

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACT
XLO
Founded
1996
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.6M
41.8M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
TACT
XLO
Price
$4.13
$0.69
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$5.00
$2.00
AVG Volume (30 Days)
32.3K
411.9K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,258,000.00
$31,804,000.00
Revenue This Year
$21.67
$626.78
Revenue Next Year
$7.63
$79.08
P/E Ratio
N/A
N/A
Revenue Growth
8.27
588.40
52 Week Low
$3.12
$0.62
52 Week High
$5.70
$1.70

Technical Indicators

Market Signals
Indicator
TACT
XLO
Relative Strength Index (RSI) 51.11 48.18
Support Level $3.67 $0.63
Resistance Level $4.07 $0.74
Average True Range (ATR) 0.18 0.03
MACD 0.01 0.01
Stochastic Oscillator 67.69 46.87

Price Performance

Historical Comparison
TACT
XLO

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: